Cutaneous toxicities of antiretroviral therapy for HIV: Part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome

Journal of the American Academy of Dermatology

Volumn 63, Issue 4, 2010, Pages 563-569

  Introcaso, Camille E ^a   Hines, Janet M ^a   Kovarik, Carrie L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

antiretroviral medications; cutaneous; drug eruption; HIV; immune reconstitution syndrome; toxicities

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIHISTAMINIC AGENT; ANTIPRURITIC AGENT; CETIRIZINE; DELAVIRDINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; GLUCOCORTICOID; INTEGRASE INHIBITOR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; STEROID; TENOFOVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CYST; DERMATITIS; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE SCLEROSIS; LIPODYSTROPHY; MOUTH ULCER; NIGHTMARE; NONHUMAN; PRIORITY JOURNAL; PUSTULOSIS; RECOMMENDED DRUG DOSE; REVIEW; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; URTICARIA; XEROSTOMIA; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ERUPTIONS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; INCIDENCE; MALE; MEDICAL EDUCATION; PATHOPHYSIOLOGY; RISK ASSESSMENT;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; EDUCATION, MEDICAL, CONTINUING; FEMALE; FOLLOW-UP STUDIES; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MALE; RISK ASSESSMENT;

EID: 77956762257     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.02.059     Document Type: Review

References (63)

1. Derisi M, Ballard C, Abulhosn K, Colwell B, Mathews WC. Sulfa-associated rash and race are risk factors for non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated rash (abstract). Presented at The 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30-February 2, 2000.
2. R.B. Pollard, P. Robinson, and K. Dransfield Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection Clin Ther 20 1998 1071 1092
3. J. Ananworanich, Z. Moor, U. Siangphoe, J. Chan, P. Cardiello, and C. Duncombe Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs AIDS 19 2005 185 192
4. K.J. Warren, D.E. Boxwell, N.Y. Kim, and B.A. Drolet Nevirapine- associated Stevens-Johnson syndrome Lancet 351 1998 567
5. A. Calmy, B. Hirschel, D.A. Cooper, and A. Carr Clinical update: adverse effects of antiretroviral therapy Lancet 370 2007 12 14
6. S.M. Patel, S. Johnson, S.M. Belknap, J. Chan, B.E. Sha, and C. Bennett Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals J Acquir Immune Defic Syndr 35 2004 120 125
7. J. Hitti, L.M. Frenkel, A.M. Stek, S.A. Nachman, D. Baker, and A. Gonzalez-Garcia Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022 J Acquir Immune Defic Syndr 36 2004 772 776
8. L. Jamisse, J. Balkus, J. Hitti, S. Gloyd, R. Manuel, and N. Osman Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in mozambique receiving nevirapine-based regimens J Acquir Immune Defic Syndr 44 2007 371 376
9. F. van Leth, S. Andrews, B. Grinsztejn, E. Wilkins, M.K. Lazanas, and J.M. Lange The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART AIDS 19 2005 463 471
10. A.L. Panlilio, D.M. Cardo, L.A. Grohskopf, W. Heneine, C.S. Ross U.S. Public Health Service. Updated U.S Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis MMWR Recomm Rep 54 2005 1 17
11. N. Phanuphak, T. Apornpong, S. Teeratakulpisarn, S. Chaithongwongwatthana, C. Taweepolcharoen, and S. Mangclaviraj Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women HIV Med 8 2007 357 366
12. A. Antinori, F. Baldini, E. Girardi, A. Cingolani, M. Zaccarelli, and S. Di Giambenedetto Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy AIDS 15 2001 1579 1581
13. C. Scully, and P. Diz Dios Orofacial effects of antiretroviral therapies Oral Dis 7 2001 205 210
14. H.H. Kong, and S.A. Myers Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients Dermatol Ther 18 2005 58 66
15. M.D. Moura, M.I. Senna, D.F. Madureira, L.M. Fonseca, and R.A. Mesquita Oral adverse effects due to the use of nevirapine J Contemp Dent Pract 9 2008 84 90
16. J.P. Fagot, M. Mockenhaupt, J.N. Bouwes-Bavinck, L. Naldi, C. Viboud, and J.C. Roujeau Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis AIDS 15 2001 1843 1848
17. A.R. Mason, G.Y. Cortes, and R.B. Pollack Nevirapine-induced Stevens-Johnson syndrome in a pediatric patient Pediatr Dermatol 25 2008 128 129
18. H. Knobel, J.M. Miró, P. Domingo, A. Rivero, M. Mrquez, and L. Force Failure of a short-term prednisone regimen to prevent nevirapine- associated rash: A double-blind placebo-controlled trial: The GESIDA 09/99 study J Acquir Immune Defic Syndr 28 2001 14 18
19. P. Anton, V. Soriano, I. Jimenez-Nacher, R. Rodriguez-Rosado, M.C. Dona, and P.M. Barreiro Incidence of rash and discontinuation of nevirapine using two different escalating initial doses AIDS 13 1999 524 525
20. R.T. Davey Jr., D.G. Chaitt, G.F. Reed, W.W. Freimuth, B.R. Herpin, and J.A. Metcalf Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients Antimicrob Agents Chemother 40 1996 1657 1664
21. G. Mills, J. Morgan, G. Hales, and D. Smith Acute hypersensitivity with delavirdine Antivir Ther (Lond) 4 1999 51
22. L.J. Scott, and C.M. Perry Delavirdine: A review of its use in HIV infection Drugs 60 2000 1411 1444
23. S.E. Starr, C.V. Fletcher, S.A. Spector, F.H. Yong, T. Fenton, and R.C. Brundage Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team N Engl J Med 341 1999 1874 1881
24. R.M. Gulick, H.J. Ribaudo, C.M. Shikuma, S. Lustgarten, K.E. Squires, and W.A. Meyer 3rd Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection N Engl J Med 350 2004 1850 1861
25. S.A. Riddler, R. Haubrich, A.G. DiRienzo, L. Peeples, W.G. Powderly, and K.L. Klingman Class-sparing regimens for initial treatment of HIV-1 infection N Engl J Med 358 2008 2095 2106
26. F. Forna, C.A. Liechty, P. Solberg, F. Asiimwe, W. Were, and J. Mermin Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda J Acquir Immune Defic Syndr 44 2007 456 462
27. J.A. Perez-Molina Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients HIV Clin Trials 3 2002 279 286
28. A. Carr, and D.A. Cooper Adverse effects of antiretroviral therapy Lancet 356 2000 1423 1430
29. Sustiva [package insert] 2008 Bristol-Meyers Squibb Company New York
30. U. Mehta, and G. Maartens Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 7 2007 733 738
31. A. Lazzarin, T. Campbell, B. Clotet, M. Johnson, C. Katlama, and A. Moll Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 39 48
32. J.V. Madruga, D. Berger, M. McMurchie, F. Suter, D. Banhegyi, and K. Ruxrungtham Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial Lancet 370 2007 49 58
33. TMC125-C223 Writing Group J.P. Nadler, D.S. Berger, G. Blick, P.J. Cimoch, and C.J. Cohen Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis AIDS 21 2007 F1 F10
34. Intelence [package insert] 2008 Tibotec Therapeutics Titusville, NJ
35. A. Lazzarin, B. Clotet, D. Cooper, J. Reynes, K. Arasteh, and M. Nelson Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia N Engl J Med 348 2003 2186 2195
36. J.P. Lalezari, K. Henry, M. O'Hearn, J.S. Montaner, P.J. Piliero, and B. Trottier Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America N Engl J Med 348 2003 2175 2185
37. M.A. Beilke Acute hypersensitivity reaction to enfuvurtide upon re-challenge Scand J Infect Dis 36 2004 778
38. J.A. DeSimone, A. Ojha, R. Pathak, and J. Cohn Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man Clin Infect Dis 39 2004 e110 e112
39. E. Shahar, C. Moar, and S. Pollack Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction AIDS 19 2005 451 452
40. R.A. Ball, T. Kinchelow ISR Substudy Group Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide J Am Acad Dermatol 49 2003 826 831
41. S.S. Lieberman-Blum, H.B. Fung, and J.C. Bandres Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection Clin Ther 30 2008 1228 1250
42. T.H. Evering, and M. Markowitz Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1 Drugs Today (Barc) 43 2007 865 877
43. R.T. Steigbigel, D.A. Cooper, P.N. Kumar, J.E. Eron, M. Schechter, and M. Markowitz Raltegravir with optimized background therapy for resistant HIV-1 infection N Engl J Med 359 2008 339 354
44. I. Ratnam, C. Chiu, N.B. Kandala, and P.J. Easterbrook Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort Clin Infect Dis 42 2006 418 427
45. B. Knoll, B. Lassmann, and Z. Temesgen Current status of HIV infection: A review for non-HIV-treating physicians Int J Dermatol 46 2007 1219 1228
46. J. Luther, and M.J. Glesby Dermatologic adverse effects of antiretroviral therapy: recognition and management Am J Clin Dermatol 8 2007 221 233
47. D. Kerob, A. Dupuy, M.D. Vignon-Pennamen, I. Bournerias, E. Dohin, and C. Lebbe A case of efflorescence of cutaneous warts as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected patient Clin Infect Dis 45 2007 405 406
48. A. Handisurya, A. Rieger, A. Bankier, A. Koller, A. Salat, and G. Stingl Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy Br J Dermatol 157 2007 788 794
49. S. Handa, and J.S. Bingham Dermatological immune restoration syndrome: does it exist? J Eur Acad Dermatol Venereol 15 2001 430 432
50. M. Nacher, V. Vantilcke, A. Mahamat, M. El Guedj, T. Vaz, and A. Randrianjohany Increased incidence of cutaneous mycoses after HAART initiation: A benign form of immune reconstitution disease? AIDS 21 2007 2248 2250 (Pubitemid 350287225)
51. J. Pelgrom, I. Bastian, E. Van den Enden, F. Portaels, and R. Colebunders Cutaneous ulcer caused by Mycobacterium avium and recurrent genital herpes after highly active antiretroviral therapy Arch Dermatol 136 2000 129
52. N.A. Qazi, J.F. Morlese, J.C. Walsh, C.B. Bunker, N. Francis, and M.R. Nelson Case report. Severe cutaneous ulceration secondary to cytomegalovirus inclusion disease during successful immune reconstitution with HAART AIDS Read 12 2002 452 454
53. L.K. Rodrigues, T. Baker, and T. Maurer Cutaneous warts in HIV-positive patients undergoing highly active antiretroviral therapy Arch Dermatol 137 2001 1103 1104
54. A.P. Steenhoff, S.M. Wood, S.S. Shah, and R.M. Rutstein Cutaneous Mycobacterium avium complex infection as a manifestation of the immune reconstitution syndrome in a human immunodeficiency virus-infected child Pediatr Infect Dis J 26 2007 755 757
55. J. Gasiorowski, B. Knysz, B. Szetela, and A. Gladysz Cutaneous cryptococcosis as a rare manifestation of the immune reconstitution syndrome in an HIV-1-infected patient Postepy Hig Med Dosw (Online) 62 2008 1 3
56. S. Antinori, E. Longhi, G. Bestetti, R. Piolini, V. Acquaviva, and A. Foschi Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome Br J Dermatol 157 2007 1032 1036
57. S.D. Lawn Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy Curr Opin Infect Dis 20 2007 482 488
58. S.D. Lawn, T.A. Bicanic, and D.C. Macallan Pyomyositis and cutaneous abscesses due to mycobacterium avium: an immune reconstitution manifestation in a patient with AIDS Clin Infect Dis 38 2004 461 463
59. H.M. Crane, H. Deubner, J.C. Huang, P.E. Swanson, and R.D. Harrington Fatal Kaposi's sarcoma-associated immune reconstitution following HAART initiation Int J STD AIDS 16 2005 80 83
60. A.J. Chamberlain, K. Hollowood, R.J. Turner, and I. Byren Tumid lupus erythematosus occurring following highly active antiretroviral therapy for HIV infection: A manifestation of immune restoration J Am Acad Dermatol 51 5 suppl 2004 S161 S165
61. G. Roustan, M. Yebra, O. Rodriguez-Braojos, I. Banos, J. Jaurena, and A. Simon Cutaneous and pulmonary sarcoidosis in a patient with HIV after highly active antiretroviral therapy Int J Dermatol 46 2007 68 71
62. J.F. Silvestre, M.P. Albares, R. Ramon, and R. Botella Cutaneous intolerance to tattoos in a patient with human immunodeficiency virus: A manifestation of the immune restoration syndrome Arch Dermatol 137 2001 669 670
63. M. Brown, I.G. Williams, and R.F. Miller Deterioration of disseminated cutaneous mycobacterium avium complex infection with a leukaemoid reaction following institution of highly active antiretroviral therapy Sex Transm Infect 77 2001 149 150